Biktarvy is an antiviral medication owned by Gilead Sciences Inc. The active ingredients in Biktarvy are Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate. The drug was first authorized for market use on 07 February 2018. It is available in tablet form and is mainly used in the treatment of HIV infection.
There are a total of 13 drug patents for Biktarvy, out of which 1 has already expired. Patent challenges can be filed against Biktarvy from 07 February 2022. The last patent for Biktarvy, titled 'Therapeutic compositions for treatment of human immunodeficiency virus', is expected to expire on 08 November 2036. Therefore, Biktarvy generic versions may become available after this date.
Biktarvy is used in the treatment of HIV infection. Its active ingredients, Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate, work together to inhibit the replication of the HIV virus in patients' bodies, thereby reducing the amount of the virus present.
There are 13 drug patents related to Biktarvy, owned by Gilead Sciences Inc. The last patent of Biktarvy, titled 'Therapeutic compositions for treatment of human immunodeficiency virus', is expected to expire on 08 November 2036, after which potential Biktarvy generic alternatives could be released. Below are the details of the patents: